Skip to content
ModernDocHealth
Contact

Skip to section

Psychiatry

What the Latest Research Reveals

Data last updated: 38 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.

33.6%
Receive a psychiatric diagnosis within 6 months of COVID-19
— including 12.8% first-ever diagnoses
Source: Taquet et al.. Lancet Psychiatry (2021). 10.1016/S2215-0366(21)00084-5 | n=236379

KEY FINDINGS

Any Psychiatric Diagnosis
+44%
95% CI: HR 1.44 (95% CI: 1.40-1.47)
Source [1]
Psychosis Risk
+116%
95% CI: HR 2.16 (95% CI: 1.62-2.88)
Source [1]
Cognitive Impairment
22%
95% CI: Prevalence (95% CI: 18-27%)
Source [12]
Depression
+39%
95% CI: HR 1.39 (95% CI: 1.33-1.46)
Source [1]
Risk of depressive symptoms 3 years after COVID-19 in adults with Long COVID vs without
aRR 1.86
95% CI: 95% CI: 1.34-2.57
Source [26]
Risk of anxiety symptoms 3 years after COVID-19 in adults with Long COVID vs without
aRR 1.60
95% CI: 95% CI: 1.18-2.16
Source [27]
Risk of persistent depressive symptoms at 3-year follow-up relative to no symptoms at either follow-up in adults with Long COVID
RR 2.64
95% CI: 95% CI: 1.60-4.35
Source [28]
Risk of persistent anxiety symptoms at both follow-ups relative to no symptoms at either follow-up in adults with Long COVID
RR 2.48
95% CI: 95% CI: 1.38-4.47
Source [29]
Depressive symptoms 3 years after initial infection in adults with Long COVID
aRR 1.86
95% CI: 95% CI: 1.34-2.57
Source [30]
Anxiety symptoms 3 years after initial infection in adults with Long COVID
aRR 1.60
95% CI: 95% CI: 1.18-2.16
Source [31]
Persistent depressive symptoms at 3-year follow-up relative to no symptoms at either follow-up in Long COVID patients
RR 2.64
95% CI: 95% CI: 1.60-4.35
Source [32]
Persistent anxiety symptoms at both follow-ups relative to no symptoms at either follow-up in Long COVID patients
RR 2.48
95% CI: 95% CI: 1.38-4.47
Source [33]
Depressive symptoms at 3 years post-infection in Long COVID vs. no Long COVID
aRR 1.86
95% CI: 95% CI: 1.34-2.57
Source [34]
Anxiety symptoms at 3 years post-infection in Long COVID vs. no Long COVID
aRR 1.60
95% CI: 95% CI: 1.18-2.16
Source [35]
Persistent depressive symptoms at 3-year follow-up relative to no symptoms at either follow-up
RR 2.64
95% CI: 95% CI: 1.60-4.35
Source [36]
Persistent anxiety symptoms at both follow-ups relative to no anxiety symptoms at either follow-up
RR 2.48
95% CI: 95% CI: 1.38-4.47
Source [37]
Cognitive impairment prevalence in long COVID populations
25%
95% CI: 95% CI: 23-27
Source [38]
Brain fog prevalence in long COVID populations
30%
95% CI: 95% CI: 28-32
Source [38]

THE TIMELINE

Acute Phase

0-4 weeks

28-84% delirium in hospitalized/ICU patients

Key Event
Delirium & acute stress

6-Month Psychiatric Diagnosis Risk

Source: Taquet et al., Lancet Psychiatry 2021 (HR 1.44 vs influenza)

Cumulative Mental Health Risk with Reinfection

1 infection+33.6%
2 infections+~60%
3+ infections+~84%

“Each reinfection compounds your mental health burden”

THE HOPEFUL HORIZON

  • Standard antidepressants remain effective for post-COVID depression[1]
  • Post-COVID psychosis often resolves within 3-6 months with treatment[2]
  • Telehealth expands access to mental health care and therapy[18]
  • Integrated Long COVID clinics improve psychiatric outcomes

SOURCES

  1. [1]Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. DOI (opens in new tab)
  2. [2]Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1,284,437 patients. Lancet Psychiatry. 2022;9(10):815-827. DOI (opens in new tab)
  3. [3]Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-2270. DOI (opens in new tab)
  4. [4]Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021;9(3):239-250. DOI (opens in new tab)
  5. [5]Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044. DOI (opens in new tab)

See a problem with the Psychiatry research summary?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction

SHARE THIS INFORMATION

Share with someone who needs to know

Back to DashboardReport an Issue

Data last updated:

Medical review: AI-generated — pending clinician review

Sources cited: 38 peer-reviewed sources

Claim verification: 0/0 verified (NaN%)

About DOIs

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for medical decisions. Data is sourced from peer-reviewed publications and may be updated as new research emerges.